Abstract
Under normal circumstances, most energy substrate used for heart contraction derives from fatty acids in the form of nonesterified fatty acids bound to albumin or fatty acids derived from lipolysis of lipoprotein-bound triglyceride by lipoprotein lipase (LpL). By creating LpL knockout mice (hLpL0), we learned that loss of cardiac LpL leads to myocardial dysfunction; therefore, neither nonesterified fatty acids nor increased glucose metabolism can replace LpL actions. hLpL0 mice do not survive abdominal aortic constriction and they develop more heart failure with hypertension. Conversely, we created a mouse overexpressing cardiomyocyte-anchored LpL. This transgene produced cardiac lipotoxicity and dilated cardiomyopathy. Methods to alter this phenotype and the causes of other models of lipotoxicity are currently being studied and will provide further insight into the physiology of lipid metabolism in the heart.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
van der Vusse GJ, Glatz JF, Stam HC, Reneman RS: Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992, 72:881–940.
Lopaschuk GD, Belke DD, Gamble J, et al.: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994, 1213:263–276.
Blanchette-Mackie EJ, Masuno H, Dwyer NK, et al.: Lipoprotein lipase in myocytes and capillary endothelium of heart: immunocytochemical study. Am J Physiol 1989, 256:E818–E828.
Augustus AS, Kako Y, Yagyu H, Goldberg IJ: Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 2003, 284:E331–E339.
Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693–707.
Augustus AS, Buchanan J, Park TS, et al.: Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006, 281:8716–8723.
Iemitsu M, Miyauchi T, Maeda S, et al.: Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 2002, 283:H1750–H1760.
Moncrieff J, Lindsay MM, Dunn FG: Hypertensive heart disease and fibrosis. Curr Opin Cardiol 2004, 19:326–331.
Noh HL, Okajima K, Molkentin JD, et al.: Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab 2006, 291:E755–E760.
Sukonina V, Lookene A, Olivecrona T, Olivecrona G: Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A 2006, 103:17450–17455.
Yu X, Burgess SC, Ge H, et al.: Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc Natl Acad Sci U S A 2005, 102:1767–1772.
Ricart-Jane D, Cejudo-Martin P, Peinado-Onsurbe J, et al.: Changes in lipoprotein lipase modulate tissue energy supply during stress. J Appl Physiol 2005, 99:1343–1351.
Seip RL, Angelopoulos TJ, Semenkovich CF: Exercise induces human lipoprotein lipase gene expression in skeletal muscle but not adipose tissue. Am J Physiol 1995, 268:E229–E236.
Ruge T, Svensson M, Eriksson JW, Olivecrona G: Tissue-specific regulation of lipoprotein lipase in humans: effects of fasting. Eur J Clin Invest 2005, 35:194–200.
Deshaies Y, Geloen A, Paulin A, et al.: Tissue-specific alterations in lipoprotein lipase activity in the rat after chronic infusion of isoproterenol. Horm Metab Res 1993, 25:13–16.
Stam H, Hulsmann WC: Effects of hormones, amino acids and specific inhibitors on rat heart heparin-releasable lipoprotein lipase and tissue neutral lipase activities during long-term perfusion. Biochim Biophys Acta 1984, 794:72–82.
Gouni-Berthold I, Oka K, Berthold HK, Chan L: Failure of the nonselective beta-blocker propranolol to affect lipoprotein lipase gene expression in the rat. Lipids 1997, 32:943–947.
Cryer A, Jones HM: The distribution of lipoprotein lipase (clearing factor lipase) activity in the adiposal, muscular and lung tissues of ten animal species. Comp Biochem Physiol B 1979, 63:501–505.
Husbands DR: The distribution of lipoprotein lipase in tissues of the domestic fowl and the effects of feeding and starving. Br Poult Sci 1972, 13:85–90.
Bonnet M, Leroux C, Faulconnier Y, et al.: Lipoprotein lipase activity and mRNA are up-regulated by refeeding in adipose tissue and cardiac muscle of sheep. J Nutr 2000, 130:749–756.
Luiken JJ, Coort SL, Willems J, et al.: Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003, 52:1627–1634.
An D, Pulinilkunnil T, Qi D, et al.: The metabolic “switch” AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 2005, 288: E246–E253.
Levak-Frank S, Hofmann W, Weinstock PH, et al.: Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density lipoprotein-cholesterol levels. Proc Natl Acad Sci U S A 1999, 96:3165–3170.
Zhou YT, Grayburn P, Karim A, et al.: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784–1789.
Finck BN, Lehman JJ, Leone TC, et al.: The cardiac phenotype induced by PPAR-alpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121–130.
Finck BN, Han X, Courtois M, et al.: A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003, 100:1226–1231.
Nohammer C, Brunner F, Wolkart G, et al.: Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Lab Invest 2003, 83:259–269.
Yagyu H, Chen G, Yokoyama M, et al.: Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003, 111:419–426.
Listenberger LL, Ory DS, Schaffer JE: Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001, 276:14890–14895.
Yang J, Sambandam N, Han X, et al.: CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007, 100:1208–1217.
Lee Y, Naseem RH, Duplomb L, et al.: Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A 2004, 101:13624–13629.
Yokoyama M, Yagyu H, Hu Y, et al.: Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004, 279:4204–4211.
Rangwala SM, Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004, 25:331–336.
Vikramadithyan RK, Hirata K, Yagyu H, et al.: Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 2005, 313:586–593.
Golfman LS, Wilson CR, Sharma S, et al.: Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005, 289:E328–E336.
Son N, Park T, Yamashita H, et al.: Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction. J Clin Invest 2007, Epub ahead of print.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J., Goldberg, I.J. Lipoprotein lipase-derived fatty acids: Physiology and dysfunction. Current Science Inc 9, 462–466 (2007). https://doi.org/10.1007/s11906-007-0085-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-007-0085-4